Floatz logo

[64Cu]Cu-AKY-2519

B7H3

Aktis Oncology, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the B7H3 cohort.

Asset / SponsorPhaseRating
[225Ac]Ac-AKY-2519
Aktis Oncology, Inc.
Phase 1CC
[68Ga] B7H3 Affibody-BCH
Peking University Cancer Hospital & Institute
Early Phase 1C

Same molecule, other indications

[64Cu]Cu-AKY-2519 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
prostate cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →